Infinimmune, a California startup, is developing treatments it claims might last longer and be more effective than existing atopic dermatitis medications.

Galderma Laboratories has landed a blow on Sanofi in its multi-case advertising row, driving the French drugmaker to change ...

By Bhanvi Satija LONDON, July 30 (Reuters) - Sanofi raised its full-year sales forecast on Thursday, on the back of strong demand for blockbuster asthma drug Dupixent and newer products, as investors ...

Following a challenge brought by Galderma Laboratories, L.P., BBB National Programs' National Advertising Division found certain challenged claims made by Sanofi S.A. supported but recommended that ...

Late-breaking presentation at ACG 2023 showed histologic and endoscopic improvements were maintained with no new safety signals to week 52 with higher dose Dupixent in these children Data reinforce ...

On Friday, the FDA extended the target action date of priority review of supplemental application seeking approval for Dupixent (dupilumab) as an add-on maintenance treatment in certain adult patients ...

Sanofi’s vaccines segment had a negative 4.7% YoY growth in Q2’26, being dragged down by flu and COVID-19. Learn why SNY ...

She pledged to revive Sanofi’s R&D pipeline. Research costs rose nearly 18% in Q2 to €2.2B, including costs from pipeline prioritizations. The company discontinued more than eight development programs ...

Approval represents the second dermatology indication for Dupixent and fifth disease indication overall in the U.S. TARRYTOWN, N.Y. and PARIS, Sept. 28, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals, ...

Dupixent is a prescription injection that treats several conditions, including eczema, asthma, COPD, and rhinosinusitis. A copay card may assist you with Dupixent’s cost. Dupixent is a brand-name ...

With all the fretting from the pharmaceutical industry about competition from China, patent protection losses, price reduction initiatives and other government measures with the potential to hit pr | ...